Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Related to this article

340B Drug Pricing, Johnson & Johnson, J&J, PHRMA, Drug Price Discounts

September 18th, 2026

Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data

Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.

Prenatal COVID-19, COVID-19 Exposure, Maternal COVID-19

September 20th, 2026

Study Finds No Neurodevelopmental Risk in Prenatal COVID-19, Except Speech

Researchers assess the neurological outcomes of over 200,000 children exposed to COVID-19 before birth.

September 19th, 2026

Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies

Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.

September 18th, 2026

Generic Drug Costs Burdening Patients as Much as Brand Name Options

Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.

September 18th, 2026

PAINWeek 2026: Weaving the Threads of Pain Management

Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.

September 18th, 2026

Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID

The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.